Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Managing Lenalidomide-Caused Rash in MM patients
Leuk Lymphoma; 2016 Nov; Barley, He, et al
Lowering immunomodulatory therapy dose can reduce rash from lenalidomide treatment in people with multiple myeloma (MM), according to a retrospective analysis involving 52 individuals.
Investigators looked at MM patients who were taking thalidomide, lenalidomide, and pomalidomide (IMiDs) and developed rash. Among the results:
- Nearly all rashes were morbilliform; 45% were grade 3–4 per NCI-CTCAE criteria.
- IMiDs were initially withheld in 62% of patients; one-fourth received a short course of higher dose steroids.
- 8 in every 10 were reexposed to the same IMiD, often at a reduced dose.
- 57% were switched from weekly dexamethasone to prednisone 3 times a week.
- 93% of those reexposed to the same IMiD tolerated and continued treatment.
- 14% of those reexposed experienced rash; most of the time it was grade 1–2.
Citation:
Barley K, He W, Agarwal S, Jagannath S, Chari A. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016;57(11):2510-2515. doi:10.3109/10428194.2016.1151507.